

## Maratha Vidya Prasarak Samaj's Dr. Vasantrao Pawar Medical College, Hospital & Research Centre



Vasantdada nagar, Adgaon, Nashik, Maharashtra - 422 003

## (Annexure 3) Continuing Review/ Annual report format

EC Ref. No.(for office use)\_\_\_\_\_

*The annual report must be duly submitted no later than 30 days before the annual year's completion.			
Title	e of study:		
Prin	cipal Investigator (Name, Designation and Affiliation)		
1.	EC Reference No.:		
2.	Date of EC Approval:	Duration of Approval months/ years	
3.	Date of Start of study:	Proposed date of Completion: Click here to enter a date.	
	Period of Continuing Report	То	
4.	Does the study involve recruitment of participants?  (a) If yes, Total number expected No. Screened: No. Enrolled: Number Completed: No. on followup:  (b) Enrolment status – ongoing / completed/ stopped  (c) Report of DSMB <sup>16</sup> Yes No NA		
	(e) Have any participants withdrawn from this study since the last approval? Yes No If yes, total number withdrawn and reasons:		
5.	Is the study likely to extend beyond the stated period <sup>17</sup> ?  If yes, please provide reasons for the extension  Yes  No  No		
6.	Have there been any amendments in the research protocol/informed consent document (ICD) durit past approval period?  If No, skip to item no.6  Yes No  No  (a) If yes, date of approval for protocol and ICD: Click here to enter a date.		
(b) In case of amendments in the research protocol/ICD, was re-consent sought from part If yes, when / how:  Yes  N			

<sup>&</sup>lt;sup>16</sup>In case there is a Data Safety Monitoring Board (DSMB) for the study provide a copy of the report from the DSMB. If not write NA. <sup>17</sup>Problems encountered since the last continuing review application with respect to implementation of the protocol as cleared by the EC



## Maratha Vidya Prasarak Samaj's Dr. Vasantrao Pawar Medical College, Hospital & Research Centre



Vasantdada nagar, Adgaon, Nashik, Maharashtra - 422 003

7.	Is any new information available that changes the benefit -risk analysis of human par in this study?  If yes, discuss in detail:	ticipants involved Yes No D		
8.	Have any ethical concerns occurred during this period?  If yes, give details	Yes No No		
9.	(a) Have any adverse events been noted since the last review?Yes No			
	Describe in brief:  (b) Have any SAE's occurred since last review?  If yes, number of SAE's:  (c) Is the SAE related to the study?  Have you reported the SAE to EC? If no, state reasons  Yes No			
10.	Has there been any protocol deviations/violations that occurred during this period?			
	If yes, number of deviations  Have you reported the deviations to EC? If no, state reasons	Yes No No		
11.	In case of multicentric trials, whether reports of off-site SAEs have been submitted to Yes	the EC		
12.	Are there any publications or presentations during this period? If yes give details	Yes No No		
13. Brief Summary of the Study (up to 500 words) (to briefly describe the status, findings, activities undertaken, any deviations or changes, special mentions etc.)				
	Signature of PI:			
Date:				